MANNKIND CORP Senior Notes
MANNKIND CORP (MNKD) had Senior Notes of $36.28 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Liabilities › Debt › Long-Term Debt, Unclassified
us-gaap:SeniorNotes · last filed 2026-02-26
- 2025-12-31: Senior Notes $36.28M.
- 2024-12-31: Senior Notes $36.05M.
- 2024-09-30: Senior Notes $227.94M.
- 2024-06-30: Senior Notes $227.58M.
| Period end | Senior Notes |
|---|---|
| 2025-12-31 | $36.28M 10-K · filed 2026-02-26 |
| 2024-12-31 | $36.05M 10-K · filed 2026-02-26 |
| 2024-09-30 | $227.94M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $227.58M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $227.21M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $226.85M 10-K · filed 2025-02-26 |
| 2023-09-30 | $226.49M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $226.12M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $225.76M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $225.40M 10-K · filed 2024-02-27 |
| 2022-09-30 | $225.03M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $224.67M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $224.31M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $223.94M 10-K · filed 2023-02-23 |
| 2021-09-30 | $223.58M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $223.22M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $222.85M 10-Q · filed 2021-05-12 |
| 2019-12-31 | $10.03M 10-K · filed 2020-02-25 |
| 2018-12-31 | $19.10M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |